The effect of an aloe polymannose multinutrient complex on cognitive and immune functioning in Alzheimer's disease

John E Lewis, H. Reginald Mcdaniel, Marc E. Agronin, David Loewenstein, Jorge Riveros, Rafael Mestre, Mairelys Martinez, Niurka Colina, Dahlia Abreu, Janet Konefal, Judi Woolger, Karriem H. Ali

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Alzheimer's disease (AD) is a leading killer of Americans, imparts a significant toll on the quality of life of the patient and primary caregiver, and results in inordinate costs in an already overburdened medical system. Prior studies on cholinesterase inhibitors among AD patients have shown minimal amelioration of disease symptoms and/or restoration of lost cognitive functioning. The effect of improved nutrition, particularly with dietary supplements, on cognitive functioning may offer an alternative strategy compared to standard treatment. The present pilot study investigated the effect of an aloe polymannose multinutrient complex (APMC) formula on cognitive and immune functioning over 12 months among adults diagnosed with AD. Subjects participated in an open-label trial and consumed 4 teaspoons per day of the APMC. The ADAS-cog, MMSE, ADCS-ADL, and SIB were administered at baseline and 3, 6, 9, and 12 months follow-up. Cytokines and lymphocyte and monocyte subsets were assessed at baseline and 12 months. The mean ADAS-cog cognition score significantly improved at 9 and 12 months from baseline, and 46% of our sample showed clinically-significant improvement (≥4-point change) from baseline to 12 months. Participants showed significant decreases in tumor necrosis factor-α, vascular endothelial growth factor, and interleukins-2 and-4. CD90+, CD95+CD3+, CD95+CD34+, CD95+CD90+, CD14+CD34+, CD14+CD90+, and CD14+CD95+ decreased significantly, whereas CD14+ significantly increased. Participants tolerated the APMC supplement with few, temporary adverse reactions. Our results showed improvements in both clinical and physiological outcomes for a disease that otherwise has no standard ameliorative remedy.

Original languageEnglish
Pages (from-to)393-406
Number of pages14
JournalJournal of Alzheimer's Disease
Volume33
Issue number2
DOIs
StatePublished - Jan 23 2013

Fingerprint

Aloe
Alzheimer Disease
Cholinesterase Inhibitors
Lymphocyte Subsets
Activities of Daily Living
Dietary Supplements
Interleukin-4
Cognition
Vascular Endothelial Growth Factor A
Caregivers
Interleukin-2
Monocytes
Tumor Necrosis Factor-alpha
Quality of Life
Cytokines
Costs and Cost Analysis
polymannose
Therapeutics

Keywords

  • Aloe
  • Alzheimer disease
  • B-lymphocyte subsets
  • cognition
  • cytokines
  • dietary supplementation
  • growth factors
  • oligosaccharides
  • T-cell subsets

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Geriatrics and Gerontology
  • Clinical Psychology

Cite this

The effect of an aloe polymannose multinutrient complex on cognitive and immune functioning in Alzheimer's disease. / Lewis, John E; Mcdaniel, H. Reginald; Agronin, Marc E.; Loewenstein, David; Riveros, Jorge; Mestre, Rafael; Martinez, Mairelys; Colina, Niurka; Abreu, Dahlia; Konefal, Janet; Woolger, Judi; Ali, Karriem H.

In: Journal of Alzheimer's Disease, Vol. 33, No. 2, 23.01.2013, p. 393-406.

Research output: Contribution to journalArticle

Lewis, JE, Mcdaniel, HR, Agronin, ME, Loewenstein, D, Riveros, J, Mestre, R, Martinez, M, Colina, N, Abreu, D, Konefal, J, Woolger, J & Ali, KH 2013, 'The effect of an aloe polymannose multinutrient complex on cognitive and immune functioning in Alzheimer's disease', Journal of Alzheimer's Disease, vol. 33, no. 2, pp. 393-406. https://doi.org/10.3233/JAD-2012-121381
Lewis, John E ; Mcdaniel, H. Reginald ; Agronin, Marc E. ; Loewenstein, David ; Riveros, Jorge ; Mestre, Rafael ; Martinez, Mairelys ; Colina, Niurka ; Abreu, Dahlia ; Konefal, Janet ; Woolger, Judi ; Ali, Karriem H. / The effect of an aloe polymannose multinutrient complex on cognitive and immune functioning in Alzheimer's disease. In: Journal of Alzheimer's Disease. 2013 ; Vol. 33, No. 2. pp. 393-406.
@article{b2b5fdc57f894823926d758e45b59bcb,
title = "The effect of an aloe polymannose multinutrient complex on cognitive and immune functioning in Alzheimer's disease",
abstract = "Alzheimer's disease (AD) is a leading killer of Americans, imparts a significant toll on the quality of life of the patient and primary caregiver, and results in inordinate costs in an already overburdened medical system. Prior studies on cholinesterase inhibitors among AD patients have shown minimal amelioration of disease symptoms and/or restoration of lost cognitive functioning. The effect of improved nutrition, particularly with dietary supplements, on cognitive functioning may offer an alternative strategy compared to standard treatment. The present pilot study investigated the effect of an aloe polymannose multinutrient complex (APMC) formula on cognitive and immune functioning over 12 months among adults diagnosed with AD. Subjects participated in an open-label trial and consumed 4 teaspoons per day of the APMC. The ADAS-cog, MMSE, ADCS-ADL, and SIB were administered at baseline and 3, 6, 9, and 12 months follow-up. Cytokines and lymphocyte and monocyte subsets were assessed at baseline and 12 months. The mean ADAS-cog cognition score significantly improved at 9 and 12 months from baseline, and 46{\%} of our sample showed clinically-significant improvement (≥4-point change) from baseline to 12 months. Participants showed significant decreases in tumor necrosis factor-α, vascular endothelial growth factor, and interleukins-2 and-4. CD90+, CD95+CD3+, CD95+CD34+, CD95+CD90+, CD14+CD34+, CD14+CD90+, and CD14+CD95+ decreased significantly, whereas CD14+ significantly increased. Participants tolerated the APMC supplement with few, temporary adverse reactions. Our results showed improvements in both clinical and physiological outcomes for a disease that otherwise has no standard ameliorative remedy.",
keywords = "Aloe, Alzheimer disease, B-lymphocyte subsets, cognition, cytokines, dietary supplementation, growth factors, oligosaccharides, T-cell subsets",
author = "Lewis, {John E} and Mcdaniel, {H. Reginald} and Agronin, {Marc E.} and David Loewenstein and Jorge Riveros and Rafael Mestre and Mairelys Martinez and Niurka Colina and Dahlia Abreu and Janet Konefal and Judi Woolger and Ali, {Karriem H.}",
year = "2013",
month = "1",
day = "23",
doi = "10.3233/JAD-2012-121381",
language = "English",
volume = "33",
pages = "393--406",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "2",

}

TY - JOUR

T1 - The effect of an aloe polymannose multinutrient complex on cognitive and immune functioning in Alzheimer's disease

AU - Lewis, John E

AU - Mcdaniel, H. Reginald

AU - Agronin, Marc E.

AU - Loewenstein, David

AU - Riveros, Jorge

AU - Mestre, Rafael

AU - Martinez, Mairelys

AU - Colina, Niurka

AU - Abreu, Dahlia

AU - Konefal, Janet

AU - Woolger, Judi

AU - Ali, Karriem H.

PY - 2013/1/23

Y1 - 2013/1/23

N2 - Alzheimer's disease (AD) is a leading killer of Americans, imparts a significant toll on the quality of life of the patient and primary caregiver, and results in inordinate costs in an already overburdened medical system. Prior studies on cholinesterase inhibitors among AD patients have shown minimal amelioration of disease symptoms and/or restoration of lost cognitive functioning. The effect of improved nutrition, particularly with dietary supplements, on cognitive functioning may offer an alternative strategy compared to standard treatment. The present pilot study investigated the effect of an aloe polymannose multinutrient complex (APMC) formula on cognitive and immune functioning over 12 months among adults diagnosed with AD. Subjects participated in an open-label trial and consumed 4 teaspoons per day of the APMC. The ADAS-cog, MMSE, ADCS-ADL, and SIB were administered at baseline and 3, 6, 9, and 12 months follow-up. Cytokines and lymphocyte and monocyte subsets were assessed at baseline and 12 months. The mean ADAS-cog cognition score significantly improved at 9 and 12 months from baseline, and 46% of our sample showed clinically-significant improvement (≥4-point change) from baseline to 12 months. Participants showed significant decreases in tumor necrosis factor-α, vascular endothelial growth factor, and interleukins-2 and-4. CD90+, CD95+CD3+, CD95+CD34+, CD95+CD90+, CD14+CD34+, CD14+CD90+, and CD14+CD95+ decreased significantly, whereas CD14+ significantly increased. Participants tolerated the APMC supplement with few, temporary adverse reactions. Our results showed improvements in both clinical and physiological outcomes for a disease that otherwise has no standard ameliorative remedy.

AB - Alzheimer's disease (AD) is a leading killer of Americans, imparts a significant toll on the quality of life of the patient and primary caregiver, and results in inordinate costs in an already overburdened medical system. Prior studies on cholinesterase inhibitors among AD patients have shown minimal amelioration of disease symptoms and/or restoration of lost cognitive functioning. The effect of improved nutrition, particularly with dietary supplements, on cognitive functioning may offer an alternative strategy compared to standard treatment. The present pilot study investigated the effect of an aloe polymannose multinutrient complex (APMC) formula on cognitive and immune functioning over 12 months among adults diagnosed with AD. Subjects participated in an open-label trial and consumed 4 teaspoons per day of the APMC. The ADAS-cog, MMSE, ADCS-ADL, and SIB were administered at baseline and 3, 6, 9, and 12 months follow-up. Cytokines and lymphocyte and monocyte subsets were assessed at baseline and 12 months. The mean ADAS-cog cognition score significantly improved at 9 and 12 months from baseline, and 46% of our sample showed clinically-significant improvement (≥4-point change) from baseline to 12 months. Participants showed significant decreases in tumor necrosis factor-α, vascular endothelial growth factor, and interleukins-2 and-4. CD90+, CD95+CD3+, CD95+CD34+, CD95+CD90+, CD14+CD34+, CD14+CD90+, and CD14+CD95+ decreased significantly, whereas CD14+ significantly increased. Participants tolerated the APMC supplement with few, temporary adverse reactions. Our results showed improvements in both clinical and physiological outcomes for a disease that otherwise has no standard ameliorative remedy.

KW - Aloe

KW - Alzheimer disease

KW - B-lymphocyte subsets

KW - cognition

KW - cytokines

KW - dietary supplementation

KW - growth factors

KW - oligosaccharides

KW - T-cell subsets

UR - http://www.scopus.com/inward/record.url?scp=84872467702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872467702&partnerID=8YFLogxK

U2 - 10.3233/JAD-2012-121381

DO - 10.3233/JAD-2012-121381

M3 - Article

C2 - 22976077

AN - SCOPUS:84872467702

VL - 33

SP - 393

EP - 406

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 2

ER -